Comprehensive analysis of mitophagy-related genes reveals prognostic signatures in breast cancer: based on immune landscapes and treatment target predict.
[BACKGROUND] Breast cancer (BC) is a common malignant tumor with high incidence and mortality rates.
APA
Zhao H, Zhang W, et al. (2026). Comprehensive analysis of mitophagy-related genes reveals prognostic signatures in breast cancer: based on immune landscapes and treatment target predict.. Frontiers in immunology, 17, 1740830. https://doi.org/10.3389/fimmu.2026.1740830
MLA
Zhao H, et al.. "Comprehensive analysis of mitophagy-related genes reveals prognostic signatures in breast cancer: based on immune landscapes and treatment target predict.." Frontiers in immunology, vol. 17, 2026, pp. 1740830.
PMID
41727445
Abstract
[BACKGROUND] Breast cancer (BC) is a common malignant tumor with high incidence and mortality rates. Mitophagy refers to a selective form of autophagy that is believed to be closely related to the occurrence and progression of BC. Identifying the mitophagy-related sites associated with BC can help us gain a deeper understanding of the underlying mechanisms of BC, laying the foundation for early diagnosis and effective treatment of BC.
[METHOD] RNA-seq expression data of BC were obtained from the GEO and TCGA databases. Differentially expressed genes were intersected with mitophagy-related genes from GeneCards to identify BC-associated mitophagy genes. Prognostic biomarkers were screened using Kaplan-Meier (K-M) survival and ROC analyses. Based on mitophagy-related gene expression and survival data, BC patients were classified into high- and low-risk subgroups for immune infiltration and GSEA analyses. Finally, IHC data from the HPA database and experiments, including siRNA-mediated knockdown, Western blot, CCK-8 proliferation assay, confocal microscopy and drug prediction were performed to validate the expression and biological functions of candidate biomarkers PBK and NEK2.
[RESULT] Through dual validation of K-M survival analysis and ROC diagnosis-treatment efficacy analysis, we ultimately identified 9 mitophagy-related prognostic biomarkers for BC, and found their expression was significantly upregulated in BC tissues. In addition, the results showed that the degree of immune infiltration in the low-risk subgroup was considered higher than that in the high-risk subgroup. Inhibition of PBK and NEK2 will have an inhibitory effect on the proliferation of BC cell. Furthermore, clinicopathological analyses confirmed a genuinely higher risk in the high-risk subgroup, with PBK and NEK2 independently associated with risk stratification.
[CONCLUSION] This study elucidated the prognostic value, immune microenvironment characteristics, and molecular mechanisms of mitophagy in BC, and identified nine mitophagy-related biomarkers. Among them, PBK and NEK2 were experimentally confirmed to promote tumor cell proliferation, providing novel insights for early diagnosis and therapeutic strategies in breast cancer.
[METHOD] RNA-seq expression data of BC were obtained from the GEO and TCGA databases. Differentially expressed genes were intersected with mitophagy-related genes from GeneCards to identify BC-associated mitophagy genes. Prognostic biomarkers were screened using Kaplan-Meier (K-M) survival and ROC analyses. Based on mitophagy-related gene expression and survival data, BC patients were classified into high- and low-risk subgroups for immune infiltration and GSEA analyses. Finally, IHC data from the HPA database and experiments, including siRNA-mediated knockdown, Western blot, CCK-8 proliferation assay, confocal microscopy and drug prediction were performed to validate the expression and biological functions of candidate biomarkers PBK and NEK2.
[RESULT] Through dual validation of K-M survival analysis and ROC diagnosis-treatment efficacy analysis, we ultimately identified 9 mitophagy-related prognostic biomarkers for BC, and found their expression was significantly upregulated in BC tissues. In addition, the results showed that the degree of immune infiltration in the low-risk subgroup was considered higher than that in the high-risk subgroup. Inhibition of PBK and NEK2 will have an inhibitory effect on the proliferation of BC cell. Furthermore, clinicopathological analyses confirmed a genuinely higher risk in the high-risk subgroup, with PBK and NEK2 independently associated with risk stratification.
[CONCLUSION] This study elucidated the prognostic value, immune microenvironment characteristics, and molecular mechanisms of mitophagy in BC, and identified nine mitophagy-related biomarkers. Among them, PBK and NEK2 were experimentally confirmed to promote tumor cell proliferation, providing novel insights for early diagnosis and therapeutic strategies in breast cancer.
MeSH Terms
Humans; Mitophagy; Breast Neoplasms; Female; Prognosis; Biomarkers, Tumor; Gene Expression Regulation, Neoplastic; NIMA-Related Kinases; Cell Line, Tumor; Tumor Microenvironment; Gene Expression Profiling
같은 제1저자의 인용 많은 논문 (5)
- Beyond Epilepsy Control: Repurposing Antiepileptic Drugs in Central Nervous System Tumor Therapy.
- Mechanisms Influencing Neoadjuvant Treatment Decision-Making in Patients With Locally Advanced Gastric Cancer: An Analysis Based on the Ottawa Decision Support Framework.
- Dysregulated inflammatory cytokines in MSM living with HIV who exhibited suboptimal immune reconstitution despite antiretroviral therapy (ART).
- SUMOylation and anticancer drug resistance.
- F-FDG PET-based ensemble deep learning model for the prediction of lymphovascular invasion in colorectal cancer patients.